Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

OTHER 17INDUSTRY 5UNKNOWN 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Stomach Neoplasms 12Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Sarcoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1NSCLC 1Metastatic Castration Resistant Prostate Cancer 1Malignant Neoplasms of Digestive Organs 1Fallopian Tube Neoplasms 1Cytochrome P450 Interaction 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced Primary Liver Cancer 1Advanced Cancer 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × apatinib × Clear all
NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
210 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03267654 2020-08-03

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Qilu Pharmaceutical Co., Ltd.

Phase 2 Unknown
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02332512 2017-02-24

ANSWER

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01270386 2012-02-10

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
136 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡